KQB198 in Combination With Imatinib in Participants With Advanced/​Metastatic GIST in 1st Line Setting

KQB198 in Combination With Imatinib in Participants With Advanced/​Metastatic GIST in 1st Line Setting

Gastrointestinal Stromal Tumor

Recruiting

2

Start Date 04/14/2026

Age of Trial (yrs) .2

First-line

RAS Pathway inhibitor

Block KIT + Block KIT Signal Path

Specifically GIST and only GIST

KQB198-103

Kumquat Biosciences Inc.

Kumquat Clinical Development 858-214-2700 kumquatstudies@kumquatbio.com

Brief Summary
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Inclusion Criteria (Partial - follow the NCT link to clinicaltrials.gov to see the full Eligibility criteria)

All Participants:

Unresectable or metastatic disease
Tissue confirmation of GIST
Valid results from local testing of blood or tumor tissue documenting the presence of a KIT mutation (must not have exon 9 mutation) or PDGFRA mutation (must not have PDGFRA D842V).
Measurable disease per RECIST v1.1.
Patients must be in 1st line of treatment for advanced or metastatic disease. Prior imatinib is allowed in adjuvant or neoadjuvant setting, as long as imatinib was stopped over 1 year ago.